Receiver operator curve plots for prognostication of 5-year and 12-year all-cause (A and C, respectively) and cardiovascular mortality (B and D, respectively)

Slides:

Advertisements

Similar presentations

Risk Stratification In Patients With Chronic Myocardial Ischemia.

Advertisements

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

First-pass perfusion images through the short axis, 2-chamber views.

Example of Subendocardial Defects With Normal Transmural WT on Apical 3-Chamber View With RTMCE Apical 3-chamber view of RTMCE with power modulation (iE33,

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Masashi Maeda et al. Heart Asia 2013;5:7-14

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Intramural segment with no ischaemia in a patient with an intramural segment of an AAORCA (A and B, asterix), there is normal rest and stress perfusion.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.

The volume per centre plotted against clinical outcomes which included Hospital Anxiety and Depression Scale (HADS) score, exercise 150 min, smoking, body.

Comparative receiver operating characteristic (ROC) curves and the area under the curve (AUC) in association with 30-day mortality for severity scores.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

The continuous curvilinear relationship between arm exercise scores and 5-year and 12-year all-cause (A and C, respectively) and cardiovascular survival.

(A) ROC for the prediction of 5-year mortality in unoperated significant MR. AUCs and corresponding p values are shown for lateral annulus E/E′ (AUC=0.69,

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

Cumulative survival without events during the first 42 days of treatment with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril (n=351)

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Scatter plot of estimated joint density of incremental costs and incremental effects (quality-adjusted life years (EuroQol five-dimension questionnaire,

Multiple-beat and single-beat determination of the ESPDR

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Reduction of cardiac enzyme release by ischaemic postconditioning (PostC), adjusted on the area at risk (AAR). Reduction of cardiac enzyme release by ischaemic.

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Bland-Altman plots for intra and inter observer variability for the assessment of total Agatston score for patients with a calcium score less than 1000.

Assessment of infarct size by biomarker measurement.

Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.

Representative images of coronary angiography and fractional flow reserve (FFR) from a patient who showed no resting ECG abnormality. Representative images.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Relation between institutional volume and MRRUF

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

The fractional flow reserve (FFR) values according to increasing risks of the Multifunction CardioGram (MCG) scores. The fractional flow reserve (FFR)

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Survival curves according to the presence of late gadolinium enhancement (LGE) and elevated high-sensitivity C reactive protein (hs-CRP). Survival curves.

ROC curves showing additive value of DHE in diagnosing ongoing episode of recurrence among all patients with established history of recurrent pericarditis.

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

Calculating the overall accuracy in different samples using the V-plot

Forest plot of all-cause mortality (ACM) in CRT patient with AF comparing atrioventricular junction ablation (AVJA) versus no AVJA. AF, atrial fibrillation;

Activation and desensitization of the α7 nAChRs.

Sestamibi scan of patient 5 showing a fixed defect (indicating infarction) in the anterior wall (small arrowheads) and reversible ischaemia in the septum.

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

The QT interval responses to different pacing rates in a patient in group I. The pacing rate was decreased from 110 to 50 beats/min and the QT interval.

Left Ventricular Mass at MRI and Long-Term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Left ventricular hypertrophy.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Independent predictors of all-cause mortality at 30 days.

Profile of diastolic function parameters at rest, immediately post-exercise and into recovery. Profile of diastolic function parameters at rest, immediately.

Forest plot of major bleeding: the measure of the effect of morphine versus nonmorphine on major bleeding in each study was plotted using OR and 95% CI.

Forest plot illustrating the risk ratio of myocardial infarction

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Receiver operating characteristic curve showing results for two selected models, applied to the testing cohort. Receiver operating characteristic curve.

Presentation transcript:

Receiver operator curve plots for prognostication of 5-year and 12-year all-cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with arm exercise scores (Arm Score AUC), best fit model pharmacological myocardial perfusion imag... Receiver operator curve plots for prognostication of 5-year and 12-year all-cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with arm exercise scores (Arm Score AUC), best fit model pharmacological myocardial perfusion imaging (MPI) study predictors (perfusion defect number, type and size and the change in heart rate from rest to peak stress;7 Best fit pharm MPI AUC), and an abnormal versus normal pharmacological MPI result (Abn pharm MPI AUC), for 1730 pharmacological evaluations performed during the same 1997–2002 time interval. AUC, area under the curve. Yan Xie et al. Open Heart 2016;3:e000333 ©2016 by British Cardiovascular Society